RARE vs TECH · rev $560.2M vs P/E 65, rev $1.22B
Ultragenyx (RARE) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
RARE currently screens at market cap $2.79B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the RARE and TECH stock pages for the full models.
Not investment advice.